BLRX - Rasio rega marang prakiraan pendapatan BioLineRx

BioLineRx Ltd. (BLRX) hedges biotech risks by combining early-stage research with the sale of drugs for genetic and oncological pathologies. The forward revenue multiple demonstrates a gradual decline in asset valuation, with the metric currently standing at 4.80. The drug Aphexda optimizes stem cell collection in hematology, while the development strategy is based on Asian distribution without mergers.

BioLineRx Ltd - Prakiraan rega marang pendapatan BLRX (periode 28.03.2024 - 13.11.2026)

Rincian metrik komprehensif lan analitis BioLineRx Corporation (BLRX)

- rega pasar lan target rega analis:

Bagan rega BioLineRx|BLRX - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar BioLineRx Corporation|BLRX - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham BioLineRx|BLRX - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih biolinerx.com|BLRX - Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas BioLineRx Ltd.|BLRX - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas BioLineRx Ltd.|BLRX - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku BioLineRx Corporation|BLRX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioLineRx|Likuiditas cepet biolinerx.com

- rincian asil keuangan lan kelipatan valuasi:

BLRX - Bathi pungkasan|Proyeksi bathi mangsa ngarep BioLineRx Ltd.|BLRX - Pangali P/E|Rega marang bathi mangsa ngarep BioLineRx Corp|BLRX - Rasio kapitalisasi marang bathi lan wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BioLineRx Corporation|BLRX - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) BioLineRx|BLRX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan biolinerx.com|BLRX - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep BioLineRx Ltd.

- data pendapatan lan penerimaan dodolan:

BLRX - Total pendapatan perusahaan|Prakiraan pendapatan perusahaan BioLineRx|BLRX - Rasio rega marang pendapatan|Multiplikator Forward P/S BioLineRx Corporation

Analisis umum perusahaan:BioLineRx BLRX

This ratio determines the market value of the business relative to its expected annual sales, allowing an investor to assess the extent of the premium paid for future cash flow. By analyzing the forward P/S metric, you can see the capitalization dynamics of BioLineRx Ltd. (BLRX) as the company transitions to commercial sales of its oncology drug and expands distribution across the US and Asia.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte INCY|Hutchison MediPharma - Rasio rega marang prakiraan pendapatan|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One Biopharmaceuticals Inc|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan inhibrx.com INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharma FENC|Multiplikator forward rega marang pendapatan HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (corbuspharma.com)|Cardiff Oncology Corp - Multiplikator Forward P/S|Rega forward marang dodolan BYSI (BeyondSpring, Inc.)|BCAB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Lixte Biotechnology, Inc. (LIXT)|Rasio rega marang prakiraan pendapatan Citius Pharmaceuticals Inc.|CLRB: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S aprea.com (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep chimerix.com|CYCC: Multiplikator Forward P/S|GTHX (G1 Therapeutics) - Rasio rega marang prakiraan pendapatan|KRON (Kronos Bio Corp) - Multiplikator Forward P/S|Kintara Pharma (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Oncternal Therapeutics (ONCT)|PRTG - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep